Merck (MRK) signs a deal to use GE Healthcare's (GE) Flutemetamol imaging agent in clinical...

|About: Merck & Co Inc. (MRK)|By:, SA News Editor

Merck (MRK) signs a deal to use GE Healthcare's (GE) Flutemetamol imaging agent in clinical studies of Merck's MK-8931 drug for treating Alzheimer's disease. Flutemetamol, which performed well in its own Phase III trials, helps detect beta amyloid deposits in the brain. The build-up of beta amyloid has been associated with Alzheimer's. (PR)